ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)‘s stock had its “buy” rating reissued by stock analysts at Canaccord Genuity in a report issued on Thursday, November 2nd.
A number of other research firms also recently issued reports on ANIP. Zacks Investment Research raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. BidaskClub raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $68.25.
Shares of ANI Pharmaceuticals (NASDAQ ANIP) opened at $63.73 on Thursday. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $65.81. The firm has a market capitalization of $747.07, a price-to-earnings ratio of 19.14 and a beta of 2.85.
ANI Pharmaceuticals (NASDAQ:ANIP) last released its earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The business had revenue of $48.16 million for the quarter, compared to analyst estimates of $48.12 million. During the same quarter last year, the firm posted $1.09 earnings per share. The business’s revenue was up 25.0% compared to the same quarter last year. equities analysts forecast that ANI Pharmaceuticals will post 3.59 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “ANI Pharmaceuticals’ (ANIP) “Buy” Rating Reiterated at Canaccord Genuity” was originally posted by BBNS and is the property of of BBNS. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://baseballnewssource.com/markets/ani-pharmaceuticals-inc-anip-given-buy-rating-at-canaccord-genuity/1753436.html.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Texas Permanent School Fund boosted its holdings in ANI Pharmaceuticals by 1.9% in the second quarter. Texas Permanent School Fund now owns 5,863 shares of the specialty pharmaceutical company’s stock worth $274,000 after acquiring an additional 111 shares in the last quarter. Prudential Financial Inc. boosted its holdings in ANI Pharmaceuticals by 1.4% in the first quarter. Prudential Financial Inc. now owns 14,080 shares of the specialty pharmaceutical company’s stock worth $697,000 after acquiring an additional 200 shares in the last quarter. Thrivent Financial For Lutherans boosted its holdings in ANI Pharmaceuticals by 5.1% in the first quarter. Thrivent Financial For Lutherans now owns 4,520 shares of the specialty pharmaceutical company’s stock worth $224,000 after acquiring an additional 220 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in ANI Pharmaceuticals by 0.6% in the second quarter. Ameriprise Financial Inc. now owns 54,205 shares of the specialty pharmaceutical company’s stock worth $2,536,000 after acquiring an additional 340 shares in the last quarter. Finally, Dana Investment Advisors Inc. raised its stake in shares of ANI Pharmaceuticals by 0.8% in the second quarter. Dana Investment Advisors Inc. now owns 42,720 shares of the specialty pharmaceutical company’s stock worth $1,999,000 after purchasing an additional 341 shares during the last quarter. 57.66% of the stock is owned by institutional investors and hedge funds.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.